Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma

Radhika Bansal, Mizba Baksh, Jeremy T. Larsen, Matthew A. Hathcock, David Dingli, A. Keith Stewart, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R. Hayman, Rahma M. Warsame, Rafael Fonseca, P. Leif Bergsagel, Sikander Ailawadhi, Shaji K. Kumar, Yi Lin

Research output: Contribution to journalArticlepeer-review


Bone marrow (BM) assessment of minimal residual disease (MRD) is prognostic for survival in multiple myeloma (MM). BM is still hypocellular at month 1 post CAR-T, thus the value of MRD negative (MRDneg) status at this timepoint is unclear. We examined the impact of month 1 BM MRD status in MM patients who received CART at Mayo Clinic between 8/2016 and 6/2021. Among 60 patients, 78% were BM-MRDneg at month 1; and 85% (40/47) of these patients also had decreased to less than normal level of both involved and uninvolved free light chain (FLC < NL). Patients who achieved CR/sCR had higher rates of month 1 BM-MRDneg and FLC < NL. The rate of sustained BM-MRDneg was 40% (19/47). Rate of conversion from MRDpos to MRDneg was 5%(1/20). At month 1, 38%(18/47) of the BM-MRDneg were hypocellular. Recovery to normal cellularity was observed in 50%(7/14) with a median time to normalization at 12 months (range: 3–Not reached). Compared to Month 1 BM-MRDpos patients, patients who were BM-MRDneg had longer PFS irrespective of BM cellularity [PFS: 2.9 months (95% CI, 1.2-NR) vs. 17.5 months (95% CI, 10.4-NR), p < 0.0001]. Month 1 BM-MRDneg and FLC below normal were associated with prolonged survival. Our data support the continued evaluation of BM early post-CART infusion as a prognostic tool.

Original languageEnglish (US)
Article number47
JournalBlood cancer journal
Issue number1
StatePublished - Dec 2023

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma'. Together they form a unique fingerprint.

Cite this